ELISA/assay

Cytochrome P450 2C19 (CYP2C19) ELISA Kit

MBS2020154

48-Strip-Wells

650 USD

ELISA Kit

Cytochrome P450 2C19 (CYP2C19) ELISA Kit

Cytochrome P450 2C19 (CYP2C19)

cytochrome P450 2C19; Cytochrome P450 2C19; cytochrome P450 2C19; cytochrome P450, family 2, subfamily C, polypeptide 19; (R)-limonene 6-monooxygenase (EC:1.14.13.80); (S)-limonene 6-monooxygenase (EC:1.14.13.48); (S)-limonene 7-monooxygenase (EC:1.14.13.49); CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Mephenytoin 4-hydroxylase

CYP2C19

CYP2C19; CYP2C19; CPCJ; CYP2C; P450C2C; CYPIIC17; CYPIIC19; P450IIC19

CP2CJ_HUMAN

Rat

490

This assay has high sensitivity and excellent specificity for detection of CYP2C19. No significant cross-reactivity or interference between CYP2C19 and analogues was observed.

For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 degree C upon receipt while the others should be at 4 degree C. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal. The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Samples: Rat tissue homogenates, cell lysates and other biological fluids. Assay Type: Sandwich. Detection Range: 0.78 -50ng/mL. The standard curve concentrations used for the ELISA's were 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.12ng/mL, 1.56ng/mL, 0.78ng/mL. Sensitivity: The minimum detectable dose of CYP2C19 is typically less than 0.28ng/mL. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

Intended Uses: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of CYP2C19 in rat tissue homogenates, cell lysates and other biological fluids. Intra-assay Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level CYP2C19 were tested 20 times on one plate, respectively. Intra-Assay: CV<10%. Inter-assay Precision: Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level CYP2C19 were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100. Inter-Assay: CV<12%

Principle of the Assay: The microtiter plate provided in this kit has been pre-coated with an antibody specific to CYP2C19. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to CYP2C19. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain CYP2C19, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of CYP2C19 in the samples is then determined by comparing the O.D. of the samples to the standard curve.

4503219

NP_000760.1

NM_000769.2

P33261

55,931 Da

Arachidonic Acid Metabolism Pathway (82991); Arachidonic Acid Metabolism Pathway (685553); Arachidonic Acid Metabolism Pathway (366); Biological Oxidations Pathway (105698); CYP2E1 Reactions Pathway (105705); Chemical Carcinogenesis Pathway (673221); Chemical Carcinogenesis Pathway (673237); Cytochrome P450 - Arranged By Substrate Type Pathway (105700); Defective CYP11A1 Causes Adrenal Insufficiency, Congenital, With 46,XY Sex Reversal (AICSR) Pathway (1127640); Defective CYP11B1 Causes Adrenal Hyperplasia 4 (AH4) Pathway (1127641)

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]

CYP2C19: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Belongs to the cytochrome P450 family. Protein type: Lipid Metabolism - arachidonic acid; Cofactor and Vitamin Metabolism - retinol; EC 1.14.13.49; Lipid Metabolism - linoleic acid; Secondary Metabolites Metabolism - limonene and pinene degradation; EC 1.14.13.48; Xenobiotic Metabolism - metabolism by cytochrome P450; EC 1.14.13.80; Xenobiotic Metabolism - drug metabolism - cytochrome P450; Oxidoreductase. Chromosomal Location of Human Ortholog: 10q24. Cellular Component: endoplasmic reticulum membrane; intracellular membrane-bound organelle; cytoplasm. Molecular Function: (S)-limonene 6-monooxygenase activity; enzyme binding; iron ion binding; heme binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; (S)-limonene 7-monooxygenase activity; arachidonic acid epoxygenase activity; steroid hydroxylase activity; oxidoreductase activity; oxygen binding; monooxygenase activity. Biological Process: steroid metabolic process; xenobiotic metabolic process; exogenous drug catabolic process; monoterpenoid metabolic process; arachidonic acid metabolic process; epoxygenase P450 pathway; heterocycle metabolic process; drug metabolic process. Disease: Drug Metabolism, Poor, Cyp2c19-related

48-Strip-Wells

650 USD

96-Strip-Wells

895

5x96-Strip-Wells

3535

10x96-Strip-Wells

6320